{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:18:17Z","timestamp":1793405897084,"version":"4.5.0"},"reference-count":81,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,31]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The treatment of common nodal peripheral T-cell lymphomas (PTCLs), including PTCL, not otherwise specified (PTCL, NOS), anaplastic large-cell lymphomas, and T-follicular helper lymphomas, is evolving. These entities are currently treated similarly with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) for CD30-negative diseases, or brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (CHP) for CD30-positive diseases, followed by consolidation with autologous stem cell transplantation in the first remission. Ongoing improvements in PTCL classification, identification of predictive biomarkers, and development of new targeted agents will lead to more specific therapies that address the unique biologic and clinical properties of each entity. For example, widespread efforts focused on molecular profiling of PTCL, NOS is likely to identify distinct subtypes that warrant different treatment approaches. New agents, such as EZH1\/2 and JAK\/STAT pathway inhibitors, have broadened treatment options for relapsed or refractory diseases. Furthermore, promising strategies for optimizing immune therapy for PTCL are currently under investigation and have the potential to significantly alter the therapeutic landscape. Ongoing frontline study designs incorporate an understanding of disease biology and drug sensitivities and are poised to evaluate whether newer-targeted agents should be incorporated into frontline settings for various disease entities. Although current treatment strategies lump most disease entities together, future treatments will include distinct strategies for each disease subtype that optimize therapy for individuals. This movement toward individualized therapy will ultimately lead to dramatic improvements in the prognosis of patients with PTCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023021789","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T16:11:45Z","timestamp":1706890305000},"page":"1887-1897","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3408-050X","authenticated-orcid":false,"given":"Alison J.","family":"Moskowitz","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5170","authenticated-orcid":false,"given":"Robert N.","family":"Stuver","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-2006","authenticated-orcid":false,"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2024103115204839000_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024103115204839000_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"21","key":"2024103115204839000_bib3","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"de Leval","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2024103115204839000_bib4","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"17","key":"2024103115204839000_bib5","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1182\/bloodadvances.2023009953","article-title":"TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2024103115204839000_bib6","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3324\/haematol.2020.262659","article-title":"CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)","volume":"106","author":"Maura","year":"2021","journal-title":"Haematologica"},{"issue":"19","key":"2024103115204839000_bib7","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T\u00a0follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024103115204839000_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41375-021-01321-2","article-title":"High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)","volume":"36","author":"Pritchett","year":"2022","journal-title":"Leukemia"},{"issue":"18","key":"2024103115204839000_bib9","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1182\/blood.2022015451","article-title":"Clonal germinal center B cells function as a niche for T-cell lymphoma","volume":"140","author":"Fujisawa","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2024103115204839000_bib10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results\u00a0of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024103115204839000_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"2024103115204839000_bib12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18","key":"2024103115204839000_bib13","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2024103115204839000_bib14","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"S3","key":"2024103115204839000_bib15","doi-asserted-by":"crossref","first-page":"e3891642","DOI":"10.1097\/01.HS9.0000971392.38916.42","article-title":"P1124: duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 Primo Trial Expansion Phase: outcomes by baseline histology","volume":"7","author":"Mehta-Shah","year":"2023","journal-title":"Hemasphere"},{"issue":"26","key":"2024103115204839000_bib16","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A\u00a0phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024103115204839000_bib17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"2024103115204839000_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024103115204839000_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"28","key":"2024103115204839000_bib20","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children\u2019s Oncology Group study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024103115204839000_bib21","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"issue":"suppl 1","key":"2024103115204839000_bib22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2023-179304","article-title":"Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study [abstract]","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"},{"issue":"S2","key":"2024103115204839000_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hon.3163_43","article-title":"Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: primary analysis of the multinational pivotal study results (JACKPOT8)","volume":"41","author":"Kim","year":"2023","journal-title":"Hematol Oncol"},{"issue":"8","key":"2024103115204839000_bib24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"16","key":"2024103115204839000_bib25","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"issue":"S2","key":"2024103115204839000_bib26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hon.56_2879","article-title":"The combination of duvelisib and romidepsin (DR) is highly active against relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results","volume":"39","author":"Horwitz","year":"2021","journal-title":"Hematol Oncol"},{"issue":"10","key":"2024103115204839000_bib27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ajh.26288","article-title":"Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts","volume":"96","author":"Mehta-Shah","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2024103115204839000_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","article-title":"Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases","volume":"58","author":"Karube","year":"2008","journal-title":"Pathol Int"},{"issue":"10168","key":"2024103115204839000_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"suppl 1","key":"2024103115204839000_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2021-145124","article-title":"The Echelon-2 Trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) vs CHOP in frontline treatment of Pts with CD30-positive peripheral T-cell lymphoma [abstract]","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2024103115204839000_bib31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024103115204839000_bib32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hon.2320","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"35","author":"Pro","year":"2017","journal-title":"Hematol Oncol"},{"issue":"3","key":"2024103115204839000_bib33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2024103115204839000_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hon.3163_41","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: final analysis of the RO-CHOP tRIAL","volume":"41","author":"Camus","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2024103115204839000_bib35","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2021-151125","article-title":"A first-in-class STAT3 degrader KT-333 in development for treatment of hematologic cancers [abstract]","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024103115204839000_bib36","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1182\/blood-2022-162127","article-title":"A study of linperlisib in the treatment of patients with relapsed and\/or refractory peripheral T-cell lymphoma [abstract]","volume":"140","author":"Qiu","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024103115204839000_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-137782","article-title":"Cpi-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma [abstract]","volume":"136","author":"Khodadoust","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2024103115204839000_bib38","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2023-172537","article-title":"Strategies to develop anti-KIR Mab lacutamab in patients with peripheral T-cell lymphoma: preliminary monotherapy clinical data and pre-clinical combinability data [abstract]","volume":"142","author":"Iyer","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024103115204839000_bib39","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/blood-2022-159242","article-title":"DR-01, a non-fucosylated anti-CD94 antibody, depletes leukemic cells in ex vivo and in vivo models of large granular lymphocyte leukemia [abstract]","volume":"140","author":"Shi","year":"2022","journal-title":"Blood"},{"key":"2024103115204839000_bib40","doi-asserted-by":"crossref","first-page":"1291836","DOI":"10.3389\/fimmu.2023.1291836","article-title":"Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"2024103115204839000_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: The Cobalt-Lym Study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-CAS9\u2013engineered CAR T cells in patients with relapsed\/refractory (R\/R) T-cell\u00a0malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"2024103115204839000_bib42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12015-019-09937-9","article-title":"Characterization of an anti-CD5 directed CAR T-cell against T-cell malignancies","volume":"16","author":"Wada","year":"2020","journal-title":"Stem Cell Rev Rep"},{"issue":"14","key":"2024103115204839000_bib43","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarf\u00f2","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024103115204839000_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2024103115204839000_bib45","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1182\/blood-2022-165971","article-title":"First in human study of AUTO4, a TRBC1-targeting CAR T-cell therapy in relapsed\/refractory TRBC1-positive peripheral T-cell lymphoma [abstract]","volume":"140","author":"Cwynarski","year":"2022","journal-title":"Blood"},{"issue":"21","key":"2024103115204839000_bib46","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024103115204839000_bib47","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2022-156789","article-title":"Oral azacytidine in patients with relapsed\/refractory angioimmunoblastic T-cell lymphoma: final analysis of the Oracle phase III study [abstract]","volume":"140","author":"Dupuis","year":"2022","journal-title":"Blood"},{"issue":"18","key":"2024103115204839000_bib48","first-page":"2194","article-title":"Multicenter phase 2 study of oral azacitidine\u00a0(CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024103115204839000_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol Cell"},{"issue":"5","key":"2024103115204839000_bib50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1101\/gad.415507","article-title":"The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells","volume":"21","author":"Bracken","year":"2007","journal-title":"Genes Dev"},{"issue":"10","key":"2024103115204839000_bib51","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024103115204839000_bib52","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2024103115204839000_bib53","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41379-019-0254-4","article-title":"The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations","volume":"32","author":"Steinhilber","year":"2019","journal-title":"Mod Pathol"},{"issue":"8","key":"2024103115204839000_bib54","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024103115204839000_bib55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024103115204839000_bib56","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1200\/JCO.22.00272","article-title":"Crizotinib in combination with chemotherapy for pediatric patients with ALK+ anaplastic large-cell lymphoma: the results of Children\u2019s Oncology Group trial ANHL12P1","volume":"41","author":"Lowe","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"2024103115204839000_bib57","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024103115204839000_bib58","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","article-title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study","volume":"22","author":"Fischer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024103115204839000_bib59","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.3324\/haematol.2021.280081","article-title":"Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement","volume":"107","author":"Rigaud","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024103115204839000_bib60","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2019-129955","article-title":"Imatinib +\/- brentuximab vedotin induces sustained complete remission in chemotherapy-resistant anaplastic large cell lymphoma expressing PDGFR [abstract]","volume":"134","author":"Staber","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2024103115204839000_bib61","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/nm.2966","article-title":"PDGFR blockade is a rational and effective therapy for NPM-ALK\u2013driven lymphomas","volume":"18","author":"Laimer","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"2024103115204839000_bib62","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12943-022-01640-7","article-title":"PDGFR\u03b2 promotes oncogenic progression via STAT3\/STAT5 hyperactivation in anaplastic large cell lymphoma","volume":"21","author":"Garces de los Fayos Alonso","year":"2022","journal-title":"Mol Cancer"},{"issue":"6","key":"2024103115204839000_bib63","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024103115204839000_bib64","doi-asserted-by":"crossref","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"S3","key":"2024103115204839000_bib65","doi-asserted-by":"crossref","first-page":"e6843062","DOI":"10.1097\/01.HS9.0000971464.68430.62","article-title":"P1142: AFM13 in patients with R\/R peripheral T cell lymphoma (PTCL): a post-hoc subgroup analysis from the redirect study","volume":"7","author":"Kim","year":"2023","journal-title":"Hemasphere"},{"key":"2024103115204839000_bib66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fonc.2019.00259","article-title":"CAR-based approaches to cutaneous T-cell lymphoma. Mini review","volume":"9","author":"Scarf\u00f2","year":"2019","journal-title":"Front Oncol"},{"issue":"17","key":"2024103115204839000_bib67","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2024103115204839000_bib68","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024103115204839000_bib69","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"10","key":"2024103115204839000_bib70","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2024103115204839000_bib71","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A\u00a0prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"issue":"18","key":"2024103115204839000_bib72","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma study group. Clinical trial research support, non-U.S. Gov\u2019t","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2024103115204839000_bib73","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2024103115204839000_bib74","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A\u00a0multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2024103115204839000_bib75","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"issue":"2","key":"2024103115204839000_bib76","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv"},{"issue":"25","key":"2024103115204839000_bib77","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024103115204839000_bib78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2024103115204839000_bib79","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024103115204839000_bib80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-138542","article-title":"Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis [abstract]","volume":"136","author":"Mehta-Shah","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2024103115204839000_bib81","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/JCO.21.02463","article-title":"Moving beyond one size fits all for T-cell lymphoma","volume":"40","author":"Moskowitz","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/18\/1887\/2311638\/blood_bld-2023-021789-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/18\/1887\/2311638\/blood_bld-2023-021789-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T11:21:09Z","timestamp":1730373669000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/18\/1887\/514805\/Current-and-upcoming-treatment-approaches-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":81,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,10,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021789","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}